Why the study?
Does the novel renin inhibitor SR 42128 reduce blood pressure and inhibit plasma renin activity in sodium-depleted monkeys?
Does the novel renin inhibitor SR 42128 reduce blood pressure and inhibit plasma renin activity in sodium-depleted monkeys?
SR 42128 is a potent, long-acting renin inhibitor that effectively lowers blood pressure and inhibits plasma renin activity in primate models.
Answers are grounded in this paper and cite their sources.
Supports preclinical renin inhibitor validation; leaves open translation to human hypertension trials.
A new potent renin inhibitor, Iva-Phe-Nle-Sta-Ala-Sta-OH (SR 42128), and its arginine salt (SR 42128A) have been synthesized. This compound had a concentration required to displace 50% of ligand binding of 2.8 X 10(-8) M toward human plasma renin at pH 7.4 and was 2,000 times more potent than pepstatin. All primate renins tested were inhibited within the same order of magnitude whereas other animal renins were much less inhibited. The effect in vivo of SR 42128A was studied in sodium-depleted conscious monkeys. A single dose of SR 42128A produced a dose-dependent blood pressure decrease as well as a dose-dependent inhibition of plasma renin activity (PRA). Blood pressure was still significantly lowered 3 h after a single administration of 3 or 10 mg/kg whereas PRA was still completely inhibited. SR 42128 is a potent and long-acting tool for studying the role of the renin angiotensin system in primates and humans.
No takes yet. Share an insight, caveat, or question.
Clavière et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: